SWOG clinical trial number
CTSU/NRG-BR004

A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer

Open
Phase
III
Abbreviated Title
Phase III Double-Blind Trial, of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
Status Notes
Activated by NRG Oncology on 3/12/19.
Activated by SWOG: 7/24/2019
Activated
07/24/2019
Participants
ALL NATIONAL CLINICAL TRIALS NETWORK MEMBERS LISTED ON TITLE PAGE

Research committees

Breast Cancer

Treatment

Trastuzumab Pertuzumab Atezolizumab Paclitaxel

Eligibility Criteria Expand/Collapse

Eligibility criteria are accessible from the protocol abstract page on the CTSU website (http://www.ctsu.org).

Other Clinical Trials

SWOG Clinical Trial Number
CTSU/EA1151

Tomosynthesis Mammographic Imaging Screening Trial (TMIST)

Research Committee(s)
Breast Cancer
Activated
07/24/2019
Open
Phase